Longeveron

LGVN49

Penny Stock

$2.07arrow_drop_down5.85%-$0.13

Penny Stock

LGVN49

$2.07

arrow_drop_down5.85%-$0.13

Penny Stock

Performance History

Key Stats
Open	$2.03
Prev. Close	$2.09
EPS	-8.86
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$31.44M
PE Ratio	-

	LOW	HIGH
Day Range	1.97	2.11
52 Week Range	0.77	23.90

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-8.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Longeveron (LGVN)

Longeveron Inc. (LGVN) is a biotechnology company that focuses on the research and development of regenerative medicine therapies. The company's mission is to provide innovative treatments for aging-related diseases and conditions. Longeveron's primary focus is on developing therapies using stem cells derived from the bone marrow of healthy adult donors.

Longeveron's stock price history has shown volatility since the company went public. The stock initially debuted at a price of $10 per share but experienced fluctuations in the following months. As of the latest available data, the stock is trading at a price of $5 per share. It's important to note that stock prices can be influenced by various factors, including market conditions and investor sentiment.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Mohamed Wa'el Ahmed Hashad
Headquarters: Miami
Employees: 19
Exchange: NASDAQ

Keep an eye on Longeveron

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Longeveron's (LGVN) price per share?

The current price per share for Longeveron (LGVN) is $2.07. The stock has seen a price change of -$0.13 recently, indicating a -5.86% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Longeveron (LGVN)?

For Longeveron (LGVN), the 52-week high is $23.9, which is 1.05K% from the current price. The 52-week low is $0.77, the current price is 168.48% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Longeveron (LGVN) a growth stock?

Longeveron (LGVN) has shown an average price growth of -3.56% over the past three years. It has received a score of 35 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Longeveron as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Longeveron (LGVN) stock price performance year to date (YTD)?

As of the latest data, Longeveron (LGVN) has a year-to-date price change of -84.32%. Over the past month, the stock has experienced a price change of 3.5%. Over the last three months, the change has been -28.87%. Over the past six months, the figure is 13.74%.

help

Is Longeveron (LGVN) a profitable company?

Longeveron (LGVN) has a net income of -$21.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -747.86% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$21.03M. Furthermore, the EBITDA is -$17.22M.

help

What is the market capitalization of Longeveron (LGVN)?

Longeveron (LGVN) has a market capitalization of $31.88M. The average daily trading volume is 2.1, indicating the stock's liquidity and investor engagement.

News

ANNOVIS BIO

ALZHEIMER'S DISEASE

NEURODEGENERATIVE DISEASES

CLINICAL TRIALS

Sep 5, 2024

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)